China's First Expert Consensus on Clinical Drug Treatment of Osteoarthritis Releases Key Products of Peak Pharmaceutical Yueyining Selected
Release time:
2021-07-21
News from our newspaper # February 10 , the Sports Medical Branch of the Chinese Medical Association and other units jointly released the "Expert Consensus on Clinical Drug Treatment of Osteoarthritis" in Hangzhou. This is the first time that the Chinese medical community has released osteoarthritis. Related expert consensus. Peak Pharmaceuticals' key product, Yue Yining (Aceclofenac Sustained Release Tablets), is included in the consensus list of therapeutic drugs.
"Expert Consensus on Clinical Drug Treatment of Osteoarthritis" was initiated by Chen Shiyi, winner of the "Chinese Medicine Award", director of the Sports Medicine Center of Fudan University, and director of the Orthopedic Arthroscopic Diagnosis and Treatment Technology Training Base of the Ministry of Health (Shanghai), the sports medicine branch of the Chinese medical association, the sports medicine group of the orthopaedic branch of the Chinese medical association, the arthroscopic society of the orthopaedic branch of the Chinese medical association and other units organized more than 30 relevant experts to jointly compile it, which took nearly 1 years to complete. the consensus is divided into 6 parts, and the full text is nearly 2 words. The experts participating in the discussion are distributed in 27 large-scale tertiary hospitals in 16 provinces (cities, autonomous regions) across the country, involving multiple disciplines such as orthopedics, sports medicine, pain, pharmacy, and evidence-based medicine. The formulation principles of rigorous, standardized, objective, practical, and economical, adhere to the guidance of evidence-based medicine, and fully integrate the current clinical practice of osteoarthritis in China, give more than 20 best clinical medication plan.
Yueyining (Aceclofenac Sustained Release Tablets), a key product of Jianfeng Pharmaceutical, has been recognized by experts and included in the consensus by virtue of its unique advantages. In the consensus, it is clearly pointed out that patients with osteoarthritis should choose the non-steroidal anti-inflammatory drug aceclofenac, which can promote the synthesis of cartilage matrix proteoglycan, and the slow-release dosage form can be preferred, which can better control the blood concentration and improve the compliance of patients with drugs.
According to introduction, osteoarthritis is prone to occur in middle-aged and elderly people with high incidence rate. More than 50% of knee pain people over 65 years old are osteoarthritis patients, and the prevalence rate of osteoarthritis in knee pain people over 75 years old exceeds 80% . With the promotion of national centralized procurement and disease diagnosis related sub-group (DRG) payment, the price of artificial joints has dropped significantly, and doctors and the business community are faced with the choice of surgery and medication, so the launch of this consensus is timely. According to the national standardization requirements for disease treatment, both conservative treatment and drug treatment need corresponding guiding principles, which are based on guidelines and expert consensus. On the basis of being included in the expert consensus this time, Jianfeng Pharmaceutical will make every effort to carry out the promotion of the "Expert Consensus on Clinical Drug Treatment of Osteoarthritis" to further guide the safe, effective, economical and standardized use of osteoarthritis treatment drugs in clinical practice. Highlight the clinical advantages of Yueyining and better expand the market of this product.
(Xu Yuting)
More information
Shanghai Bronze Award for Outstanding Invention Went in North Carolina
News from this newspaper The results of the 31st Shanghai Excellent Invention Trial jointly organized by the Shanghai Federation of Trade Unions, Shanghai Intellectual Property Office, Shanghai Municipal Committee of the Communist Youth League, Shanghai Science and Technology Association, and Shanghai Invention Association were evaluated a few days ago. The "Quality Improvement and Industrialization Optimization of Erlotinib Hydrochloride and Its Advanced Intermediates" declared by Technology Co., Ltd. won the bronze award. Erlotinib hydrochloride is a targeted therapy drug for the treatment of non-small cell lung cancer, which can prolong the survival time and improve the quality of life of lung cancer patients. It can target and specific sites of action to kill tumor cells, and has little impact on normal tissues. It belongs to the biological and new medical technology in the field of high-tech supported by the state. In this invention, 6,7-dimethoxyquinazoline -4-one, 4-chloro -6,7-di (2-methoxyethoxy) quinazoline and 3-aminophenylacetylene are important intermediates of erlotinib hydrochloride, which is also an important intermediate of icotinib hydrochloride, the first new anti-tumor drug of tinib in China. The invention designs and adopts a new synthesis process route, which can effectively reduce the cost of raw materials, the reactions are mostly aqueous phase reactions, energy consumption and three waste emissions are reduced by about 35%, industrialization conditions are optimized, product quality is improved, and it is applied to Industrialized mass production is conducive to the production of high-quality and low-cost erlotinib hydrochloride drugs and reduces the economic burden of patients. The Shanghai Excellent Invention Trial was founded in 1987. It is an important science and technology award approved by the Shanghai Municipal Government. It not only strongly promoted the majority of employees to carry out invention and creation activities based on their posts, but also improved the order.
2020
07-31
Jiang Xiaomeng was selected as one of the top ten news figures in the building materials industry. "China Building Materials" magazine published an exclusive interview in August. The 8th issue of 2019 "China Building Materials" magazine published a few days ago. In the "Exclusive Perspective" column, it published an exclusive interview with Jiang Xiaomeng, the top ten news figures in the building materials industry in 2018, the party secretary and chairman of the group company. The selection of the top ten news figures in the national building materials industry initiated by "China Building Materials" magazine has established nearly a hundred shining figures in the industry since 1999, which has attracted widespread attention in the industry. The selection of the top ten news figures in the building materials industry in 2018 is described as follows: Jiang Xiaomeng is a scholar and practical outstanding entrepreneur. In 2018, with his strategic thinking of insight into the future, he united and led cadres and employees at all levels of Jianfeng Group to actively adapt to the new economic normal, focusing on deepening supply-side structural reforms, the "Belt and Road" initiative, and vigorously advocating corporate transformation and upgrading and high-quality development. Work, seize opportunities, reform and innovate, and achieve historic new achievements in the development of the peak 60 years. The group's overall economic efficiency and development quality have been significantly improved. In recent years, under the leadership of Jiang Xiaomeng, Jianfeng Group has seized the opportunity to join forces with central enterprises to participate in the establishment of Southern Cement, effectively integrate the cement market in Zhejiang Province, optimize the allocation of cement industry resources, and greatly improve social and economic benefits. It has a positive and far-reaching impact on the supply-side structural reform and healthy development of the cement industry in Zhejiang Province. At the same time, the long-term layout of the peak group, strategically predict the direction of national development.
2020
07-31
Jianfeng Group started from a small cement plant with an annual output of 30000 tons in 1958. Through horizontal alliance with township enterprises, the formation of enterprise groups and the implementation of joint-stock reform, Jianfeng Group took the lead in listing in China's cement industry in 1993 and explored diversified operation. In 2007, Jianfeng joined hands with the central enterprise China Building Materials to participate in the establishment of Southern Cement, which strategically shifted the focus of the cement industry, and at the same time through enterprise mergers and technological innovation, the pharmaceutical industry is growing rapidly ...... Such a long history, in the industry has a good reputation of enterprises, Zhejiang Province, the earliest existing listed companies, its head is Jiang Xiaomeng. Focus on Industry Jiang Xiaomeng has spent nearly 40 years in Jinhua Cement Factory, the predecessor of Jianfeng Group. As a witness and promoter of the development and growth of the peak, Jiang Xiaomeng said that the sustained and steady development of the peak group benefits from the long-term focus on industry, which is the value orientation of the peak and the responsibility of the enterprise. Whether there was only a single cement industry in the early stage or the diversified development after listing, all the investment projects of the peak have not left the industry. With the continuous emergence of new economic formats, many people once suggested that the peak should be transferred to the "fashionable" and rewarding industries such as the Internet, but they were all rejected. Jiang Xiaomeng explained that it is necessary to use professional people to do professional things. Peak's years of experience, talents, and resource accumulation are all in industry. Although the new format is good, it is not necessarily suitable for peak development. Take cement as an example, even in the case of peak pharmaceutical has occupied the group.
2020
07-31
Jiang Xiaomeng was selected as one of the top ten news figures in the building materials industry. "China Building Materials" magazine published an exclusive interview in August. The 8th issue of 2019 "China Building Materials" magazine published a few days ago. In the "Exclusive Perspective" column, it published an exclusive interview with Jiang Xiaomeng, the top ten news figures in the building materials industry in 2018, the party secretary and chairman of the group company. The selection of the top ten news figures in the national building materials industry initiated by "China Building Materials" magazine has established nearly a hundred shining figures in the industry since 1999, which has attracted widespread attention in the industry. The selection of the top ten news figures in the building materials industry in 2018 is described as follows: Jiang Xiaomeng is a scholar and practical outstanding entrepreneur. In 2018, with his strategic thinking of insight into the future, he united and led cadres and employees at all levels of Jianfeng Group to actively adapt to the new economic normal, focusing on deepening supply-side structural reforms, the "Belt and Road" initiative, and vigorously advocating corporate transformation and upgrading and high-quality development. Work, seize opportunities, reform and innovate, and achieve historic new achievements in the development of the peak 60 years. The group's overall economic efficiency and development quality have been significantly improved. In recent years, under the leadership of Jiang Xiaomeng, Jianfeng Group has seized the opportunity to join forces with central enterprises to participate in the establishment of Southern Cement, effectively integrate the cement market in Zhejiang Province, optimize the allocation of cement industry resources, and greatly improve social and economic benefits. It has a positive and far-reaching impact on the supply-side structural reform and healthy development of the cement industry in Zhejiang Province. At the same time, the long-term layout of the peak group, strategically predict the direction of national development.
2020
07-31
Jiang Xiaomeng was selected as one of the top ten news figures in the building materials industry. "China Building Materials" magazine published an exclusive interview in August. The 8th issue of 2019 "China Building Materials" magazine published a few days ago. In the "Exclusive Perspective" column, it published an exclusive interview with Jiang Xiaomeng, the top ten news figures in the building materials industry in 2018, the party secretary and chairman of the group company. The selection of the top ten news figures in the national building materials industry initiated by "China Building Materials" magazine has established nearly a hundred shining figures in the industry since 1999, which has attracted widespread attention in the industry. The selection of the top ten news figures in the building materials industry in 2018 is described as follows: Jiang Xiaomeng is a scholar and practical outstanding entrepreneur. In 2018, with his strategic thinking of insight into the future, he united and led cadres and employees at all levels of Jianfeng Group to actively adapt to the new economic normal, focusing on deepening supply-side structural reforms, the "Belt and Road" initiative, and vigorously advocating corporate transformation and upgrading and high-quality development. Work, seize opportunities, reform and innovate, and achieve historic new achievements in the development of the peak 60 years. The group's overall economic efficiency and development quality have been significantly improved. In recent years, under the leadership of Jiang Xiaomeng, Jianfeng Group has seized the opportunity to join forces with central enterprises to participate in the establishment of Southern Cement, effectively integrate the cement market in Zhejiang Province, optimize the allocation of cement industry resources, and greatly improve social and economic benefits. It has a positive and far-reaching impact on the supply-side structural reform and healthy development of the cement industry in Zhejiang Province. At the same time, the long-term layout of the peak group, strategically predict the direction of national development.
2020
07-30
On August 29, the group company held the 11th meeting of the 10th board of directors of the company by means of communication, and deliberated and passed the semi annual report of Jianfeng group in 2019 and the amendment of internal control system of the company. In the first half of the year, the company focused on the general work policy of "innovation and reform, integration and improvement, scientific layout, and steady development", grasping the opportunities brought by economic structure optimization and industrial upgrading externally, continuously integrating resources internally, and improving the internal management system. Improve the efficiency of enterprise operation. In the first half of 2019, the company achieved total operating income of 1.686 billion billion yuan, an increase of 12.17 percent over the same period last year, and the net profit attributable to the owners of the parent company was 0.476 billion billion yuan, an increase of 57.55 percent over the same period last year. At the end of June 2019, the Company's total assets were $5.383 billion, up 9.82 from the beginning of the year, and its net assets were $3.817 billion, up 10.64 from the beginning of the year. In the first half of the year, the company made a new breakthrough in the expansion of cement business. The group company has completed the acquisition of 100 equity of Guizhou huangpinggu longmingchuan cement co., ltd. and continues to invest in the construction of its new dry cement production line with a daily output of 4500 tons of cement clinker (with waste heat power generation). Yunnan Jianfeng invested 5 million yuan to participate in the establishment of Yunnan Jianfeng Da Zhan Cement Co., Ltd., which plans to build a cement clinker production line in lameng county, Xishuangxian Dai autonomous prefecture by capacity replacement according to relevant national policies. The company's cement subsidiaries continue to carry out in-depth "three down three improve" activities, stable.
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page